Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Haemonetics (HAE)

Haemonetics Q3 Revenue Falls 2.7%, Adjusted EPS Rises 10.1%; Raises FY2026 Guidance

Positive Impact 4 of 5 earnings Written later

Haemonetics reported third-quarter fiscal 2026 revenue of $339.0 million, down 2.7% from a year earlier, while GAAP net income rose 19.3% to $44.7 million. The company raised its fiscal 2026 adjusted earnings per diluted share guidance to $4.90 to $5.00 from $4.80 to $5.00 and raised its free cash flow guidance to $200 million to $220 million from $170 million to $210 million.

Key points

  • Q3 revenue was $339.0 million, down 2.7%; organic revenue declined 1.2%, and organic ex-CSL revenue rose 7.5%.
  • GAAP earnings per diluted share were $0.95, up from $0.74; adjusted earnings per diluted share were $1.31, up 10.1%.
  • Q3 free cash flow was $74.2 million, up 150.9%; cash on hand was $363.4 million as of December 27, 2025.
  • Fiscal 2026 adjusted earnings per diluted share guidance now $4.90 to $5.00; free cash flow guidance now $200 million to $220 million.

The filing

CompanyHaemonetics (HAE)
Form8-K, current report
Filed with the SECFeb 5, 2026, 6:03 AM ET
Accession number0000313143-26-000009

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.